Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809819 | 1.00 | HSD17B10 (0.47) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL2899162 | 1.00 | HSD17B10 (0.47) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL13547538 | 0.82 | DDB1 (0.39) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL9243943 | 0.81 | MAOB (0.44) | LMNAMAOBPKMMAOA | |
| SCHEMBL9109652 | 0.81 | MAOB (0.44) | LMNAMAOBPKMMAOA | |
| SCHEMBL2722147 | 0.81 | SLC6A3 (0.46) | — | |
| SCHEMBL2901706 | 0.81 | SLC6A3 (0.46) | — | |
| SCHEMBL5021254 | 0.81 | MAOB (0.44) | MAOB | |
| SCHEMBL20840267 | 0.81 | DDB1 (0.40) | HSD17B10USP2ALDH1A1HPGDMAOB | |
| SCHEMBL8234131 | 0.81 | USP2 (0.35) | HSD17B10USP2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110257033-B | Water-based cleaning solution and preparation method and application thereof | 中国海洋石油集团有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-110257033-A | A kind of water-base cleaning liquid and its preparation method and application | 中国海洋石油集团有限公司 | 2019-09-20 | — | — | CN | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| WO-2025149498-A1 | BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119060991-A | Reaction process for preparing (S) -4-phenyl-2-oxazolidinone with high chiral purity and biocatalyst | 宁波酶赛生物工程有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240294482-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | INNER MONGOLIA UNIVERSITY OF TECHNOLOGY (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118207195-A | Enzymatic preparation of (S) -4-phenyl-2-oxazolidinone and (S) -oxirane | 宁波酶赛生物工程有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115043810-B | Method for preparing chiral hydrocarbon bond oxidation product by non-metal catalyzed asymmetric hydrocarbon bond oxidation | 浙江大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-0037141-A1 | Purification of cyanuric acid | FMC Corporation (US) | 1981-10-07 | — | — | EP | disclosed |
| US-4282359-A | MECHANICAL SEPARATION FROM HEATED SLURRY CONTAINING UREA ANOR BIURET | FMC CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4275202-A | Production of a purified cyanuric acid dihydrate | FMC CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-4232162-A | P-Substituted N,N'-bis-(3-oxazolidinyl-2-one)phosphoramides and process for the preparation thereof | ANTIBIOTICS, S.A. (ES) | 1980-11-04 | — | — | US | disclosed |
| US-4172198-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-10-23 | — | — | US | disclosed |
| US-4009039-A | Heat developable light-sensitive oxazoline containing element | FUJI PHOTO FILM CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
| US-4007168-A | Process for preparing penicillins derivatives | PALOMO COLL A L | 1977-02-08 | — | — | US | disclosed |
| US-3947465-A | 3-Alkylsilyl-2-oxazolidonone compounds and synthesis thereof | PALOMO COLL A L | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | HSD17B10 146/4885USP2 2859/4885ALDH1A1 1460/4885 |
| US-20240294482-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | TST, CBR3, SMOX | HSD17B10 1617/4885USP2 914/4885ALDH1A1 639/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | HSD17B10 4245/4885USP2 2259/4885ALDH1A1 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.